Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bosakitug - Aclaris Therapeutics/Biosion

Next Previous
Drug Profile

Bosakitug - Aclaris Therapeutics/Biosion

Alternative Names: Anti-TSLP mAb; ATI-045; BSI-045B; TQC-2731

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosion
  • Developer Aclaris Therapeutics; Biosion; Chia Tai Tianqing Pharmaceutical Group
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Asthma; Rhinosinusitis
  • Phase II Atopic dermatitis; Chronic obstructive pulmonary disease
  • No development reported Hypersensitivity

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Allergy in China (SC, Injection)
  • 02 Jun 2025 Phase-II clinical trials in Atopic dermatitis (Parenteral) in USA (NCT07011706)
  • 08 May 2025 Aclaris Therapeutics plans a phase IIb trial for Atopic dermatitis in the second quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top